VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH
|
|
- Dortha Hubbard
- 3 years ago
- Views:
From this document you will learn the answers to the following questions:
What is a non disclosure agreement?
What does the research industry need to do to protect its patent rights?
What is the role of joint IP Publication rights?
Transcription
1 VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH Lucia Faccio, Direttore Sviluppo Ricerca Fondazione Telethon
2 Why should academia transfer technologies to industry? i. It is their obligation as publicly funded organizations ii. It generates much needed funds to the university iii. Cooperation with industry may hold scientific advantages to academia
3 Conflict of interest University Industry Curiosity driven Knowledge Academic freedom Open Disclosure Management of Knowledge for Profit Confidentiality Limited Public disclosure
4 Technology transfer: bridge the gap Industry Academia
5 Number of Products R&D spending and output 160 R&D Spend ($ Billions) $ Total NDAs NMEs 131 $ $ $25 $20 $ $10 $ Year $0 Parexel, 2008/2009; Defined Health analysis; FDA website; Phrma.org website R&D Spending
6 Externally-Sourced Programs Drive Increasing Share of Pharma Revenue Percent of Pharma Sales Derived from External Discovery Source: Defined Health 2010
7 So a Longstanding Proportional Spending Error by Pharma Will Finally Be Corrected Self-originated vs. Licensed-in US R&D Spend % R&D Spend Uncategorized % R&D Spend on Licensed-In Projects % R&D Spend on Self- Originated Project Source: Defined Health 2010
8 Without Externally Discovered Programs Few Pharmas Would Have Late Stage Pipelines Today 100% Percent of New Molecule Entity Portfolio of Top 15 Large Pharma from External Origin (i.e. In-Licensing, Company or Product Acquisition) 80% 60% 40% 20% 0% Phase 1 Phase 2 Phase 3 Marketed Source: Defined Health 2010
9 years Licensing Why do we need to patent 13 1 product on the market (cost 1.6 bl $) Clinical Ph III/ Registration Pharma Preclinical & Clinical up to Ph II Biotech 0 Basic research University potential products
10 Technology transfer is stimulating communication between very different cultures; it only works if the intermediaries have a real understanding of both cultures Tim Cook, Director ISIS Innovation - Oxford
11 What academia scientists need to know: the dont s before patenting No publication/disclosure prior to filing e.g. no article, press release, conference presentation/abstract/poster/proceedings or blog entry/ students thesis/ laboratory web pages No Material Transfer to external laboratories No lecture or presentation prior to filing except under a confidentiality agreement (CDA) Seek OBT support and advice soon! File before others do! Patenting and Publication can move together!!!
12 Non Disclosure Agreement (NDA) It is a legal contract between at least two parties that outlines confidential material, knowledge, or information that the parties wish to share with one another for certain purposes. The parties agree not to disclose to third parties information covered by the agreement. An NDA creates a confidential relationship between the parties to protect any type of confidential and proprietary information or trade secrets. As such, an NDA protects nonpublic business information.
13 Material Transfer Agreements (MTA) It is a contract that governs the transfer of tangible research materials between two organizations, when the recipient intends to use it for his or her own research purposes. The MTA defines the rights of the provider and the recipient with respect to the materials and any derivatives. Biological materials, such as reagents, cell lines, plasmids, and vectors, are the most frequently transferred materials, but MTAs may also be used for other types of materials, such as chemical compounds and even some types of software.
14 Industry - Academia collaborations: possible scenarios Know How Industrial funding to academic research Patent Rights License
15 Industrial funding to academic research Must have in an industrial collaboration contract: SPONSORED RESEARCH Know How SERVICE TO INDUSTRY Definition of background IP and Know how Definition of ownership of future results Definition of access by Pharma to future results (i.e. option, license exclusive vs non exclusive etc) Management of joint IP Publication rights and evaluation of patentability Contract Termination : access by the parties to non patentable material/know how developed during the collaboration
16 Industry - Academia collaborations: possible scenarios Know How Industrial funding to academic research Patent Rights License
17 Nine things to remember in licensing 1. Universities should reserve the right to practice licensed inventions and to allow other non-profit and governmental organizations to do so 2. Exclusive licenses should be structured in a manner that encourages technology development and use 3. Strive to minimize the licensing of future improvements 4. Universities should anticipate and help to manage technology transfer related conflicts of interest 5. Ensure broad access to research tools 6. Enforcement action should be carefully considered 7. Be mindful of export regulations 8. Be mindful of the implications of working with patent aggregators 9. Consider including provisions that address unmet needs, such as those of neglected patient populations or geographic areas, giving particular attention to improved therapeutics, diagnostics and agricultural technologies for the developing world From
18 PEER REVIEW 1. TELETHON S MISSION AND ACTIONS INTRAMURAL RESEARCH: 13.3M TIGEM Institute: genetics and medicine (Naples) HSR-TIGET Institute: gene therapy (Milan) Dulbecco Telethon Institute: career program EXTERNAL RESEARCH: 15,2 M Research projects Biobanks Collaborative programs Diagnostic, observational and palliative studies RESEARCH INVESTMENT yearly competitive call 1-3-yr funding 5-yr grant renewal (site visits/audits) PERCENT FUNDING DISTRIBUTION, % DISEASE 9% 48% 35% funding to therapeutic approaches/clinical trials 18 projects in the clinical pipeline 9% 10% Studies on mechanism Gene identification 16% CURE Clinical trials ADA-SCID In vivo therapeutic approaches In vitro therapeutic approaches MISSION TO ADVANCE BIOMEDICAL RESEARCH TOWARDS CURES FOR MUSCULAR DYSTROPHY AND OTHER GENETIC DISEASES BACKGROUND Major Italian biomedical charity focused on genetic diseases Founded in 1990 out of the wish of a group of patients Support through fundraising FIGURES M research investment 2351 research grants 1461 principal investigators 459 genetic diseases studied 7964 scientific publications AVERAGE CITES/PAPER Telethon:15.8 USA: 9.7 Italy: 7.8 EU 27: 7.3
19 STAKEHOLDERS 2. TELETHON S VISION AND STRATEGIES COLLABORATIVE STAKEHOLDER MODEL OUR VISION FOR 2015 WE WANT TO CONVERT THE RESULTS OF EXCELLENT, SELECTED AND SUSTAINED RESEARCH INTO AVAILABLE THERAPIES Research Development Delivery GENETIC DISEASES Basic research Pre-clinical studies Pre-clinical development Clinical Trials Commerc. & post market surveillance Public domain Patients A B Telethon C Pharma Co/Biotech D TELETHON S STRATEGIC PLAN CONTINUE SUPPORTING THE BEST RESEARCH ON GENETIC DISEASES BY Applying the rigorous merit-based selection developed at Telethon Seeking additional support through public funding (A) Establishing co-financing activities with other charities/ foundations/ patient organizations (B) DEVELOP THE TRANSLATIONAL DRIVE OF TELETHON RESEARCH BY: Promoting networking activities across Europe and abroad (A) Promoting involvement of patients in data / biomaterial collection and sharing (B) Potentiating IP and technology transfer activities (including results of external research) (C) Liaising with regulatory bodies for the clinical development of preclinical studies (D)
20 GSK, Fondazione Telethon and Fondazione San Raffaele to collaborate on gene therapy for rare diseases London UK 18 October 2010 GlaxoSmithKline PLC (GSK), Fondazione Telethon and Fondazione San Raffaele today announced a new strategic alliance to research and develop novel treatments to address rare genetic disorders, using gene therapy carried out on stem cells taken from the patient s bone marrow (ex vivo). The alliance capitalises on research performed at the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), a joint venture between Fondazione Telethon and Fondazione San Raffaele established since Under the terms of the agreement, GSK will gain an exclusive licence to develop and commercialise an investigational gene therapy, for ADA Severe Combined Immune Deficiency (ADA-SCID) - a rare and life-threatening immune deficiency, which affects approximately 350 children worldwide. Phase I/II studies have demonstrated the potential of this treatment option to restore long-term immune function and protect against severe infections in children with ADA deficiency. i In addition, GSK will co-develop with Fondazione Telethon and Fondazione San Raffaele, six further applications of ex vivo stem cell therapy, using a new gene transfer technology developed by HSR- TIGET scientists, with the potential to treat a range of rare disorders. This first of these will be metachromatic leukodystrophy (MLD) and Wiskott-Aldrich Syndrome (WAS). Others include; betathalassemia, mucopolysaccharoidosis type I (MPS); globoid leukodystrophy (GLD); and chronic granulomatous disorder (CGD). Clinical trials for WAS and MLD were initiated at HSR-TIGET last spring and are currently recruiting patients.
21 Thank you!
The Cell Therapy Catapult
The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing
More informationDomanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato
Domanda di innovazione nel mondo industriale. Modalità di interazione tra pubblico e privato Ennio Ongini Nicox Consiglio Nazionale delle Ricerche Quarta Giornata Informativa "Dalla ricerca al Trasferimento
More informationChallenges of Managing Collaboration Between Research Institutions and Industry- IP Related Collaboration Contracts
Challenges of Managing Collaboration Between Research Institutions and Industry- IP Related Collaboration Contracts WIPO Workshop on Innovation, Intellectual Asset Management and Successful Technology
More informationCDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis
CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis The Centre for Drug Research and Development (CDRD) and the Multiple Sclerosis Society
More informationPresented at: Jefferies 2015 Global Healthcare Conference
Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution
More informationSarah A. Haecker, PhD 1782 Humboldt Avenue Minneapolis, Minnesota 55403 612.202.6805 shaecker@celltherapygroup.com
Sarah A. Haecker, PhD 1782 Humboldt Avenue Minneapolis, Minnesota 55403 612.202.6805 shaecker@celltherapygroup.com PROFILE Successful Senior Executive, skilled in Corporate Development including Business
More informationA career on the science park
A career on the science park Onno van de Stolpe December 2014 Copyright 2014 Galapagos NV 1987 MOGEN Agricultural biotech pioneer Design of transgenic plants with improved traits Close link with Prof Schilperoort
More informationTransforming relationships Unleashing innovation
Transforming relationships Unleashing innovation Translating Discoveries Into Products A model for innovation driven economic growth Barbara Handelin, PhD 1 The Innovation Gap Economic Opportunity Industries
More informationCommercialization Procedures: Licensing, Spinoffs and Start-ups. 2011 Yumiko Hamano
Commercialization Procedures: Licensing, Spinoffs and Start-ups Outline! Different Ways of Commercialization! Privately Funded Research and IP! Licensing! Licensing Agreement! Licensing Negotiation! Start-up
More informationAnforderungen der Life-Science Industrie an die Hochschulen. Hans Widmer Novartis Institutes for BioMedical Research
Anforderungen der Life-Science Industrie an die Hochschulen Hans Widmer Novartis Institutes for BioMedical Research There s nothing more extraordinary than a normal life 2 What does industry expect from
More informationInstitute for OneWorld Health
Institute for OneWorld Health a nonprofit pharmaceutical company Oxymoron no more: nonprofits can deliver medicines for the poor of the world January 10, 2005 Victoria Hale, PhD CEO, OneWorld Health The
More informationThe Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder
The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases Scott Johnson CEO, President and Founder Introduction Broken system of medical research No fault, system
More informationQuality by Design Concept
3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,
More informationThe Biotech Business Life Cycle. The Lawyer s Role as Counselor and Advisor
The Biotech Business Life Cycle and The Lawyer s Role as Counselor and Advisor ASU February 15, 2010 1 BIOTECH BUSINESS CYCLE AN INTERDISCIPLINARY APPROACH TO LEGAL REPRESENTATION Intellectual Property
More informationMaking the most of academic drug target discoveries
Making the most of academic drug target discoveries Richard Reschen, Isis Innovation, University of Oxford The explosion of new technologies and research techniques, and encouragement from funding agencies
More informationThe Commercialization of Technology Concepts into Medical Products
The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community
More informationEudendron: an Innovative Biotech Start-up
Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description
More informationAUTM U.S. Licensing Activity Survey: FY2014
AUTM U.S. Licensing Activity Survey: FY2014 FY2014 Licensing Activity Survey AUTM s survey data show impressive gains: Record number of U.S. Patents issued Continuing increase in startups launched Growth
More informationProfile of Biomedical Research and Biotechnology Commercialization. Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Boston Along with San Francisco,
More informationDrug Safety of Stem Cells and other Novel Therapeutics
Course 1.2 Drug Safety of Stem Cells and other Novel Therapeutics 13 17 October 2014 MRC Centre for Drug Safety Science Institute of Translational Medicine University of Liverpool, Liverpool, UK European
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all
More informationMODEL INTELLECTUAL PROPERTY POLICY FOR UNIVERSITIES AND RESEARCH INSTITUTIONS
MODEL INTELLECTUAL PROPERTY POLICY FOR UNIVERSITIES AND RESEARCH INSTITUTIONS Version One Prepared by the Division for Certain Countries in Europe and Asia 1 1. Introduction 1 The Institute recognizes
More informationRoche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
More informationEVT Execute & EVT Innovate Leading drug discovery
EVT Execute & EVT Innovate Leading drug discovery Evotec AG, Nine-month 2015 Interim Report, 10 November 2015 Forward-looking statements Information set forth in this presentation contains forward-looking
More informationOrphan Pharma: pathfinders for an increasingly specialised industry
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty
More informationAn Introduction to Valuations
An Introduction to Valuations PREPARED FOR ROCKY MOUNTAIN BIOBOOSTER MAY 9 TH, 2012 An ICON plc Company Agenda Introductions Valuation methods When is a valuation appropriate? How do you maximize your
More informationHealthcare Innovation in the UK - A Royal Society of Chemistry Position Paper
Healthcare Innovation in the UK - A Royal Society of Chemistry Position Paper Introduction The pharmaceutical industry (Pharma) has made important contributions to quality of life, longevity, economic
More informationThe Cell Therapy Catapult UK Clinical Trials Database
May 2015 The UK Clinical Trials Database covers cell therapy clinical trial activity that the Cell Therapy Catapult believes to be ongoing in the UK as of May 2015. It supersedes the database of April
More informationAFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
More informationIntellectual Property. MGPA s Industry Experience program Spring 2012
Intellectual Property MGPA s Industry Experience program Spring 2012 Intellectual Property (IP): Legal Protection for Intangible Assets Copyright Patent Trademark and Trade Secrets 2 Copyright Creative
More informationTranslational research infrastructure in Neurosciences 15.06.2011/Bruxelles
ITMO Neurosciences, sciences cognitives, neurologie, psychiatrie Translational research infrastructure in Neurosciences 15.06.2011/Bruxelles ITMO Technologie pour la santé 1 NEUROSCIENCE MEDICAL CHALLENGES
More informationB 3. Biology-Biotechnology-Bridge Program. 2-year Post-Baccalaureate Program. at MIT and its Biotech Partners
B 3 Biology-Biotechnology-Bridge Program 2-year Post-Baccalaureate Program at MIT and its Biotech Partners https://biology.mit.edu/about/postbac_program MIT provides minority outreach in STEM fields at
More informationFit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing
Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing Thursday 08 October 2015 8-9 October 2015, Copenhagen (Denmark) Medicon Valley Alliance,
More informationQ&A Intellectual Property Policy
Q&A Intellectual Property Policy Table of Contents Q: Why have an Intellectual Property Policy?... 3 Q: Does the IP Policy apply to me?... 3 Q: I am primarily affiliated with another institution and am
More informationOracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries
Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be
More informationCellular Therapy and Cord Blood Market Report 2013 Page 1. Kathy Gray Worldwide Market Reports & Consulting Coordinator Select Biosciences
Cellular Therapy and Cord Blood Market Report 2013 Kathy Gray Worldwide Market Reports & Consulting Coordinator Select Biosciences k.gray@selectbio.com Select Biosciences Market Reports Website: SelectBiosciences.com/marketreports/
More informationHOT TOPICS IN IN HEALTH CARE REFORM
By Felicia Fuller Publications Manager, DAC Patient Recruitment Services The Patient Protection and Affordable Care Act (ACA), colloquially known as Obamacare, is in full effect and its impact is palpable
More informationAutomating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se
Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in
More informationMSc program Pharmaceutical Design and Engineering. Peter Heegaard, Head of Studies DTU Veterinary
MSc program Peter Heegaard, Head of Studies DTU Veterinary There is a need for Pharma graduates Pharma industry in its widest sense (see next slide) Research institutions (public and private) Consultants
More informationBOOSTING THE COMMERCIAL RETURNS FROM RESEARCH
BOOSTING THE COMMERCIAL RETURNS FROM RESEARCH Submission in response to the Discussion Paper November 2014 Page 1 ABOUT RESEARCH AUSTRALIA is an alliance of 160 members and supporters advocating for health
More informationThe Swedish Drug Development Pipeline June 2012. A survey conducted by:
The Swedish Drug Development Pipeline June 2012 A survey conducted by: Key findings More companies report clinical trials There has been a increase in number of companies contributing with information
More informationDelivering gene therapy to patients
Delivering gene therapy to patients FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements
More informationA Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field
A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field Introduction The field of regenerative medicine remains at the forefront of personalized medicine and healthcare
More informationOpen Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum
Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities
More informationAcademic Drug Discovery in the Center for Integrative Chemical Biology and Drug Discovery
Academic Drug Discovery in the Center for Integrative Chemical Biology and Drug Discovery www.pharmacy.unc.edu/cicbdd Stephen V. Frye, Ph.D. University of North Carolina Chapel Hill Outline Why Academic
More information1. What are the key strengths and weaknesses of the UK s innovation system in relation to business-university collaboration?
ABPI S RESPONSE TO THE BUSINESS, INNOVATION AND SKILLS SELECT COMMITTEE INQUIRY INTO THE STRENGTHS AND WEAKNESSES OF BUSINESS-UNIVERSITY COLLABORATION IN THE UK AND THE UK S PERFORMANCE AGAINST INTERNATIONAL
More informationThe Board reviews risks to the Company s business plan at its scheduled meetings.
Pharmaxis Ltd 1. Board responsibility The Pharmaxis Board is responsible for ensuring the Company establishes and maintains a risk management framework for the oversight and management of risk. The Board
More informationVectura Group plc. Annual Report and Accounts 2015
RNS Number : 1783Q Vectura Group plc 15 June 2015 15 June 2015 Vectura Group plc Annual Report and Accounts 2015 In accordance with the Listing Rule 9.6.1, a copy of the following document has been submitted
More informationEXECUTIVE SUMMARY Prepared for: Pharmaceutical Research and Manufacturers of America (PhRMA) Prepared by: Battelle Technology Partnership Practice
EXECUTIVE SUMMARY Prepared for: Pharmaceutical Research and Manufacturers of America (PhRMA) Prepared by: Battelle Technology Partnership Practice Battelle is the world s largest non profit independent
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationGroundbreaking Collaborative Clinical Trial Launched
Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)
More informationyour complete stem cell bank
your complete stem cell bank HYDERABAD - 88985 000 888, WARANGAL - 8297 256 777 VISAKHAPATNAM - 7799 990 774 VIJAYAWADA AND GUNTUR - 7799 990 771 NELLORE - 7799 990 772, KADAPA - 8297 256 700 RAJAHMUNDRY
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationBiobanking Pluripotent Stem Cell Lines: UK and EU regulations Glyn Stacey, UK Stem Cell Bank, NIBSC
Biobanking Pluripotent Stem Cell Lines: UK and EU regulations Glyn Stacey, UK Stem Cell Bank, NIBSC ISCT Conference, New Zealand, April 2013 April 1 st 2013 NIBSC will become part of the Medicines and
More informationClinical and Translational Science: a role for libraries
Clinical and Translational Science: a role for libraries Presented at the Science Translational Medicine Luncheon Special Libraries Association 2010 Annual Conference New Orleans, LA, on 15 June 2010.
More informationDiscover more, discover faster. High performance, flexible NLP-based text mining for life sciences
Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences It s not information overload, it s filter failure. Clay Shirky Life Sciences organizations face the challenge
More informationAriela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae
Ariela Benigni Biol.Sci.D., Ph.D. Curriculum Vitae Personal Data Name: Date and place of birth: Citizenship: E-mail: Ariela Benigni December 16, 1955 - Bergamo, Italy Italian ariela.benigni@marionegri.it
More informationEnabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV
Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute
More informationAdaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -
Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune
More informationGuidelines for health professionals about DNA / Biobanking in Europe
Guidelines for health professionals about DNA / Biobanking in Europe BIOBANKING SUMMARY A "biobank" is a: "service unit, non-profit organization for the collection and preservation of biological material
More informationUniversity Medical Centres
University Medical Centres in the Netherlands AMC UMC Utrecht University Medical Centres University Medical Centres and the Health System Reform in the Netherlands: a Position Paper In the last ten years
More informationCord Blood Bank Business Plan
Cord Blood Bank Business Plan A sample of how to create a new program Produced by the AABB subsection: Cellular Therapy Business Management with major contributions by Nicole Omer TABLE OF CONTENTS Page
More informationBiosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies
Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is
More informationTHE LINCOLN INSTITUTE OF HEALTH
THE LINCOLN INSTITUTE OF HEALTH Background The Chair in the Care of the Older Person will be part of the new Lincoln Institute of Health, a cross disciplinary research collaboration linking schools, colleges
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationBuilding Bridges to Long-Term Growth
N o 7 Building Bridges to Long-Term Growth Tanabe is working to realize its corporate philosophy of contributing to people over the world desiring to live healthy and securely through pharmaceuticals and
More informationNovel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?
Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International
More informationConference on Clinical Research for Rare Diseases September 21, 2010
1 Industry Perspective of Orphan Diseases Edward M. Kaye MD Group V.P. Clinical Research Genzyme Corporation Cambridge, MA The Rising Cost of New * $54 million (1976$) - Hansen 1985 $231 million (1987$)
More informationLegal Issues Affecting Graduate School Administrators Council of Graduate Schools 50 th Annual Meeting
Legal Issues Affecting Graduate School Administrators Council of Graduate Schools 50 th Annual Meeting December 1, 2010 Washington, D.C. Anne Bowden, University Counsel University of Maryland abowden@umd.edu
More informationDZIF-Product Development Unit (PDU)
November 29, 2013 7 th International VPM Days DZIF-Product Development Unit (PDU) - DZIF-TPMO at HZI - DZIF-OSRA at PEI Thomas Hesterkamp, Helmholtz Zentrum für Infektionsforschung Support from TPMO &
More informationOrphan Drugs & Personalised Medicine: The Patient Perspective
Orphan Drugs & Personalised Medicine: The Patient Perspective Dr. Cees Smit, Inspire2Live/VSOP/EGAN DCTF, Ede, October 8, 2014 a Patient Advocacy Platform, bringing together patients, doctors, scientists
More informationStem cells and motor neurone disease
Stem cells and motor neurone disease F Stem cell research has fuelled hope of a treatment for a variety of conditions. This information sheet explains what these cells are and how they may be used to create
More informationBayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups
Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to
More information2015 / 2016 Awards Criteria and Submission Information
9 th Annual ViE Awards 2015 / 2016 Awards Criteria and Submission Information In association with: Dear colleague, The Vaccine Industry Excellence (ViE) Awards have been created to honor and generate recognition
More informationThis is GE Healthcare
This is GE Healthcare An Overview Imagination at work Last updated July 2014 General Electric: A heritage of innovation Founded by Thomas Edison in 1878 Only company from the original 1896 Dow Jones index
More informationFORM 10 K COVANCE INC CVD. Filed: March 03, 2000 (period: December 31, 1999)
FORM 10 K COVANCE INC CVD Filed: March 03, 2000 (period: December 31, 1999) Annual report which provides a comprehensive overview of the company for the past year Table of Contents PART I ITEM 1. ITEM
More informationRutgers Mini-MBA : BioPharma Innovation
Rutgers Mini-MBA : BioPharma Innovation Ga i n t h e s k i l l s to t r a n s f o r m scientific i n n ovat i o n i n to business success www.cmd.rutgers.edu/innovation Rutgers Mini-MBA : BioPharma Innovation
More informationSMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS 2015-2 OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, FOOD AND DRUG ADMINISTRATION, AND ADMINISTRATION
More informationITALIAN CYSTIC FIBROSIS RESEARCH FOUNDATION CALL FOR GRANT APPLICATIONS YEAR 2015
ITALIAN CYSTIC FIBROSIS RESEARCH FOUNDATION CALL FOR GRANT APPLICATIONS YEAR 2015 December 15 th 2014 The Italian Cystic Fibrosis Research Foundation (FFC) funds a limited number of research projects,
More informationNovozymes use of patents
Novozymes use of patents Preben Rasmussen, Ph. D. European Patent Attorney 2 Introduction Preben Rasmussen, Department Manager for EnzymeBusiness-patents DK Civilingeniør 1988, DTU Ph D 1991, DTU European
More informationCTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
More informationApproximate cost of a single protocol amendment: $450,000
Insight brief 34% of protocol amendments are avoidable Approximate cost of a single protocol amendment: $450,000 Improving clinical development in emerging biopharma settings: How model based drug development
More information1) SCOPE OF THE PROGRAM
CALL FOR PROJECTS 2015/16 CANADA/GERMANY JOINT PROGRAM DEADLINE: 15 TH JANUARY 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany
More informationKnowledge Exchange Seldom Happens as Planned. Pinaki Bose (U of C) Amin Emad (U of A) Joey Gallant (U of A) Sandeep Chandana (U of C)
Knowledge Exchange Seldom Happens as Planned Pinaki Bose (U of C) Amin Emad (U of A) Joey Gallant (U of A) Sandeep Chandana (U of C) Logical Afterthought. Innovation seldom happens as planned. Information
More informationBuilding innovative drug discovery alliances. Profitable. Growth Go
Building innovative drug discovery alliances Innovation n & Profitable Growth Go Evotec AG, H1 Presentation, 8 th August 2012 Forward-looking statements Information set forth in this presentation contains
More informationPROMETIC LIFE SCIENCES INC.
PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.
More informationIl ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020
Il ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020 Lucia Monaco Horizon 2020 Advisory Group, Societal Challenges 1: Health, Demographic Change and Wellbeing Seminario:
More informationSystematic Drug Repurposing: Some Successes, Caveats, and Directions
Systematic Drug Repurposing: Some Successes, Caveats, and Directions Christopher P. Austin, M.D. Director, Division of Preclinical Innovation National Center for Advancing Translational Sciences National
More informationRegulatory Issues in Genetic Testing and Targeted Drug Development
Regulatory Issues in Genetic Testing and Targeted Drug Development Janet Woodcock, M.D. Deputy Commissioner for Operations Food and Drug Administration October 12, 2006 Genetic and Genomic Tests are Types
More information2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative
Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationHUNT Biosciences AS Business plan 2010-2013
HUNT Biosciences AS Business plan 2010-2013 20 August 2009 Serious about biobanking 1 Table of contents Section Page 1. Executive Summary 3 2. Vision and Mission 4 3. Strategic Objectives 5 4. Organizational
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationLife Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com
Life Science Sector Opportunities Northern Ireland investni.com Introduction Clinical trials commonly refer to testing the effectiveness of experimental drugs and are typically categorised into four phases;
More informationIt s not something you want to think about, but it s something you want to prepare for.
It s not something you want to think about, but it s something you want to prepare for. StemCyte cord blood banking offers your family a new lifesaving treatment alternative Why Bank Take the once-in-alifetime
More information2019 Healthcare That Works for All
2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. To
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationA vaccine for rheumatoid arthritis
A vaccine for rheumatoid arthritis Professor Ranjeny Thomas Founder and Director of Dendright Pty Limited Head, Autoimmunity Division, Diamantina Institute, The University of Queensland About Dendright
More informationHow Public-Private Partnerships Benefit All Stakeholders Douglas C. Throckmorton, MD Deputy Director for Regulatory Programs, CDER, FDA
How Public-Private Partnerships Benefit All Stakeholders Douglas C. Throckmorton, MD Deputy Director for Regulatory Programs, CDER, FDA September 10, 2013 Outline Need for improved science in support of
More information